Abstract

慢性骨髄性白血病に対する新たな分子標的療法

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia
Lorenzo Falchi ... Jorge E Cortes
Blood | VOL. 120
Lorenzo Falchi, et. al.Lorenzo Falchi ... Jorge E Cortes
16 Nov 2012
Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia
Mahesh Swaminathan ... Jorge E Cortes
Blood | VOL. 132
Mahesh Swaminathan, et. al.Mahesh Swaminathan ... Jorge E Cortes
29 Nov 2018
Dasatinib tyrosine kinase inhibitor as second and third line therapy in chronic myeloid leukemia: outcome of a Nepalese study
Gyan Krishna Kayashta ... Paras Kumar Acharya
Journal of Patan Academy of Health Sciences | VOL. 5
Gyan Krishna Kayashta, et. al.Gyan Krishna Kayashta ... Paras Kumar Acharya
29 Jun 2018
Dasatinib promotes apoptosis of cutaneous squamous carcinoma cells by regulating activation of ERK1/2.
Mehdi Farshchian ... Veli‐Matti Kähäri
Experimental Dermatology | VOL. 26
Mehdi Farshchian, et. al.Mehdi Farshchian ... Veli‐Matti Kähäri
20 Dec 2016
View more papers

More From: Journal of Nihon University Medical Association

Paper Title
Journal
Date
Author
An Introduction to the R Language
Tetsuya Taniguchi
Journal of Nihon University Medical Association | VOL. 82
Tetsuya TaniguchiTetsuya Taniguchi
01 Dec 2023
脳卒中ガイドライン 2021（改訂 2023）
Katsunori Shido
Journal of Nihon University Medical Association | VOL. 82
Katsunori ShidoKatsunori Shido
01 Dec 2023
The Ideals and Reality of Harvard
Hiroki Kobayashi
Journal of Nihon University Medical Association | VOL. 82
Hiroki KobayashiHiroki Kobayashi
01 Dec 2023
Clinical Practice Guideline for Chronic Kidney Disease 2023
Masanori Abe
Journal of Nihon University Medical Association | VOL. 82
Masanori AbeMasanori Abe
01 Dec 2023
View more papers